HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
The present invention relates to compositions, methods, and kits for treating cancers with HER2 targeting agents and preventing resistance thereto. In particular embodiments, non-HER2-amplified cancers are treated with HER2 targeting agents, wherein the cancer stem cells in the cancer express HER2 and/or HER2 indicator marker. The present invention also relates to compositions, methods, and kits for detecting expression of HER2 and/or a HER2 indicator marker in non-HER2-amplified cancer samples from a subject, and identifying the subject as responsive to treatment with a HER2 targeting agent and/or treating the subject with a HER2 targeting agent.
1. A method comprising:
(a) identifying a population of cancer stem cells expressing HER2 and one or more of CD44, CD24, ESA, CD20, CD105, CD90, CD326 (EpCAM), CD34, CD133, CD117, Sca-1, HES6, ALDH1, CD166, CEACAM6, CD59, and CD49f in a subject that suffers from a Stage 1 non-HER2 amplified cancer; and
(b) treating the subject having the identified population of cancer stem cells with a HER2 targeting agent.
2. The method of claim 1 , further comprising, prior to said treating, receiving information that said subject, or a sample from said subject, has been identified as having: 1) said non-HER2-amplified cancer, and 2) said cancer stem cells that express HER2 and/or a HER2 indicator marker.
3. The method of claim 2 , wherein said HER2 indicator marker comprises ALDH1.
4. The method of claim 1 , wherein subject is treated with said HER2 targeting agent as adjuvant therapy.
5. The method of claim 1 , wherein said subject has had any discernable tumors removed by surgery prior to said treating.
6. The method of claim 1 , wherein said non-HER2-amplified cancer comprises non-HER2-amplified breast cancer.
7. The method of claim 1 , wherein said cancer stem cells are breast cancer stem cells or gastric cancer stem cells.
8. The method of claim 1 , further comprising testing a cancer sample from said subject and detecting expression of HER2 and/or a HER2 indicator marker by cancer stem cells in said sample.
9. The method of claim 8 , further comprising isolating said cancer stem cells from said non-HER2-amplified cancer sample prior to said detecting.
10. The method of claim 1 , further comprising testing a cancer sample from said subject and determining that said cancer sample is a non-HER2-amplified cancer sample.
11. The method of claim 1 , wherein said HER2 targeting agent comprises an anti-HER2 antibody.
12. The method of claim 11 , wherein said anti-HER2 antibody comprises Trastuzumab.
13. A method comprising:
(a) identifying a population of cancer stem cells expressing HER2 and one or more of CD44, CD24, ESA, CD20, CD105, CD90, CD326 (EpCAM), CD34, CD133, CD117, Sca-1, HES6, ALDH1, CD166, CEACAM6, CD59, and CD49f in a subject that suffers from a Stage 1 non-HER2 amplified gastric cancer; and
(b) treating the subject having the identified population of cancer stem cells with a HER2 targeting agent.
14. A method comprising:
(a) identifying a population of cancer stem cells expressing HER2 and one or more of CD44, CD24, ESA, CD20, CD105, CD90, CD326 (EpCAM), CD34, CD133, CD117, Sca-1, HES6, ALDH1, CD166, CEACAM6, CD59, and CD49f in a subject that suffers from a Stage 1 non-HER2 amplified cancer; and
(b) treating the subject having the identified population of cancer stem cells with a HER2 targeting agent and an additional agent to prevent resistance to said HER2.
15. The method of claim 14 , wherein said additional agent blocks and/or deactivates an IL6 inflammatory loop that expands cancer stem cell populations.
16. The method of claim 15 , wherein said additional agent comprises an anti-IL6R antibody.
17. A method of treating and/or preventing resistance of cancer cells or cancer stem cells to a HER2 targeting agent comprising co-administering to a subject suffering from cancer a IL6R targeting agent and said HER2 targeting agent.